文献速递泌尿生殖与妇科肿瘤放疗

欧洲泌尿外科学会风险分层可预测根治性前列腺切除术后生化复发患者接受PSMA-PET计划性挽救放疗的结局

European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
PubMed 文献 · Radiother Oncol · 2024-03-07

本研究基于5国11中心回顾性数据库,纳入1222例PSMA-PET分期的前列腺癌患者,其中526例淋巴结阴性且EAU风险分组明确者接受挽救放疗。中位随访31.0个月,EAU低危组3年生化无进展生存率85.7%优于高危组69.4%(p=0.002),3年无转移生存率94.4%优于87.6%(p=0.005),总生存率两组无显著差异(p=0.925)。作者认为该数据支持EAU风险分组定义。

要点

  • EAU低危组3年生化无进展生存率85.7%,高危组69.4%(p=0.002)。
  • EAU低危组3年无转移生存率94.4%,高危组87.6%(p=0.005)。
  • 多因素分析中EAU风险组是生化无进展生存(HR 2.022)和无转移生存(HR 2.986)的独立预测因素。

核心结论

  • 本研究数据支持EAU风险分组定义,EAU风险分组能可靠预测根治性前列腺切除术后淋巴结阴性、挽救放疗前接受PSMA-PET分期的生化复发患者的结局。
  • 据作者所知,这是首项在接受PSMA-PET计划性挽救放疗的患者中验证EAU风险分组的研究。

研究设计与样本

  • 回顾性数据库研究,纳入5个国家11个中心的1222例PSMA-PET分期的前列腺癌患者,均因生化复发接受挽救放疗。
  • 排除淋巴结转移(pN1或cN1)或EAU风险组不明确的患者后,剩余队列共526例,包括132例低危和394例高危患者。

主要发现

  • 挽救放疗后中位随访时间为31.0个月。
  • 3年生化无进展生存率EAU低危组为85.7%,高危组为69.4%(p=0.002)。
  • 3年无转移生存率低危组为94.4%,高危组为87.6%(p=0.005)。
  • 3年总生存率低危组为99.0%,高危组为99.6%(p=0.925)。
  • 多因素分析中,EAU风险组仍是生化无进展生存的显著预测因素(p=0.003,HR 2.022,95%CI 1.262-3.239)和无转移生存的显著预测因素(p=0.013,HR 2.986,95%CI 1.262-7.058)。

关键数值与推荐

  • EAU风险分层将患者分为高危与低危两组,本研究低危组132例、高危组394例。
  • 3年生化无进展生存率低危组85.7% vs 高危组69.4%(p=0.002)。
  • 3年无转移生存率低危组94.4% vs 高危组87.6%(p=0.005)。
  • 3年总生存率低危组99.0% vs 高危组99.6%(p=0.925)。
  • 多因素分析生化无进展生存:EAU风险组p=0.003,HR 2.022,95%CI 1.262-3.239;无转移生存:p=0.013,HR 2.986,95%CI 1.262-7.058。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The European Association of Urology (EAU) proposed a risk stratification (high vs. low risk) for patients with biochemical recurrence (BR) following radical prostatectomy (RP). Here we investigated whether this stratification accurately predicts outcome, particularly in patients staged with PSMA-PET. METHODS: For this study, we used a retrospective database including 1222 PSMA-PET-staged prostate cancer patients who were treated with salvage radiotherapy (SRT) for BR, at 11 centers in 5 countries. Patients with lymph node metastases (pN1 or cN1) or unclear EAU risk group were excluded. The remaining cohort comprised 526 patients, including 132 low-risk and 394 high-risk patients. RESULTS: The median follow-up time after SRT was 31.0 months. The 3-year biochemical progression-free survival (BPFS) was 85.7 % in EAU low-risk versus 69.4 % in high-risk patients (p = 0.002). The 3-year metastasis-free survival (MFS) was 94.4 % in low-risk versus 87.6 % in high-risk patients (p = 0.005). The 3-year overall survival (OS) was 99.0 % in low-risk versus 99.6 % in high-risk patients (p = 0.925). In multivariate analysis, EAU risk group remained a statistically significant predictor of BPFS (p = 0.003, HR 2.022, 95 % CI 1.262-3.239) and MFS (p = 0.013, HR 2.986, 95 % CI 1.262-7.058). CONCLUSION: Our data support the EAU risk group definition. EAU risk grouping for BCR reliably predicted outcome in patients staged lymph node-negative after RP and with PSMA-PET before SRT. To our knowledge, this is the first study validating the EAU risk grouping in patients treated with PSMA-PET-planned SRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Scharl S, Zamboglou C, Strouthos I, et al. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiother Oncol. 2024. PMID: 38458259. doi:10.1016/j.radonc.2024.110215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。